Samuel L Whittle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1157389/publications.pdf

Version: 2024-02-01

64 papers 1,354 citations

361045 20 h-index 35 g-index

66 all docs

66 docs citations

66 times ranked 2090 citing authors

#	Article	IF	CITATIONS
1	Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. British Journal of Rheumatology, 2003, 43, 267-271.	2.5	209
2	Rotator Cuff Disease. Annals of Internal Medicine, 2015, 162, ITC1-ITC16.	2.0	73
3	Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology, 2012, 51, 1416-1425.	0.9	71
4	Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Gut, 2020, 69, 617-629.	6.1	71
5	Opioid therapy for treating rheumatoid arthritis pain. The Cochrane Library, 2011, , CD003113.	1.5	63
6	2018 APLAR axial spondyloarthritis treatment recommendations. International Journal of Rheumatic Diseases, 2019, 22, 340-356.	0.9	59
7	Neuromodulators for pain management in rheumatoid arthritis. The Cochrane Library, 2012, 1 , CD008921.	1.5	56
8	Antidepressants for pain management in rheumatoid arthritis. The Cochrane Library, 2011, , CD008920.	1.5	46
9	Active foot synovitis in patients with rheumatoid arthritis: Applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. Arthritis and Rheumatism, 2012, 64, 1316-1322.	6.7	45
10	Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. International Journal of Rheumatic Diseases, 2015, 18, 341-351.	0.9	43
11	Muscle relaxants for pain management in rheumatoid arthritis. The Cochrane Library, 2012, 1, CD008922.	1.5	40
12	Patients' experience of shoulder disorders: a systematic review of qualitative studies for the OMERACT Shoulder Core Domain Set. Rheumatology, 2019, 58, 1410-1421.	0.9	36
13	Patient satisfaction and acceptability with telehealth at specialist medical outpatient clinics during the <scp>COVID</scp> â€19 pandemic in Australia. Internal Medicine Journal, 2021, 51, 1028-1037.	0.5	35
14	The accuracy of methods for urate crystal detection in synovial fluid and the effect of sample handling: A systematic review. Clinical Rheumatology, 2013, 32, 225-232.	1.0	33
15	Quality of reporting of interventional animal studies in rheumatology: a systematic review using the ARRIVE guidelines. International Journal of Rheumatic Diseases, 2015, 18, 488-494.	0.9	32
16	Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national biologics registry. Arthritis Research and Therapy, 2017, 19, 253.	1.6	32
17	Radiographic Changes in the Knee After Meniscal Transplantation. American Journal of Sports Medicine, 1996, 24, 222-226.	1.9	31
18	The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders. Journal of Rheumatology, 2019, 46, 969-975.	1.0	25

#	Article	IF	CITATIONS
19	The Efficacy and Safety of Antidepressants in Inflammatory Arthritis: A Cochrane Systematic Review. Journal of rheumatology Supplement, The, 2012, 90, 21-27.	2.2	23
20	Opioid Analgesics for Rheumatoid Arthritis Pain. JAMA - Journal of the American Medical Association, 2013, 309, 485.	3.8	22
21	The scope, funding and publication of musculoskeletal clinical trials performed in Australia. Medical Journal of Australia, 2014, 200, 88-91.	0.8	20
22	Prolonged Remission of Chronic Reactive Arthritis Treated With Three Infusions of Infliximab. Journal of Clinical Rheumatology, 2010, 16, 79-80.	0.5	19
23	Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. International Journal of Rheumatic Diseases, 2010, 13, 12-26.	0.9	19
24	Stem cell-directed therapies for osteoarthritis: The promise and the practice. Stem Cells, 2020, 38, 477-486.	1.4	19
25	Investigating Subjective Experience and the Influence of Weather Among Individuals With Fibromyalgia: A Content Analysis of Twitter. JMIR Public Health and Surveillance, 2017, 3, e4.	1.2	19
26	Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH). Osteoarthritis and Cartilage, 2021, 29, 208-214.	0.6	18
27	The Efficacy and Safety of Opioids in Inflammatory Arthritis: A Cochrane Systematic Review. Journal of rheumatology Supplement, The, 2012, 90, 40-46.	2.2	17
28	Selection and perception of methotrexate treatment information in people with rheumatoid arthritis. International Journal of Rheumatic Diseases, 2020, 23, 805-812.	0.9	16
29	Efficacy and Safety of Neuromodulators in Inflammatory Arthritis: A Cochrane Systematic Review. Journal of rheumatology Supplement, The, 2012, 90, 28-33.	2.2	14
30	A systematic review of the effects of probiotic administration in inflammatory arthritis. Complementary Therapies in Clinical Practice, 2020, 40, 101207.	0.7	14
31	Measures of Adult Shoulder Function. Arthritis Care and Research, 2020, 72, 250-293.	1.5	13
32	Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 1432-1437.	0.5	11
33	Consensus statement on the investigation and management of nonâ€radiographic axial spondyloarthritis (nrâ€ax <scp>S</scp> p <scp>A</scp>). International Journal of Rheumatic Diseases, 2014, 17, 548-556.	0.9	10
34	Perspectives of Glucocorticoid Use in Patients with Rheumatoid Arthritis. ACR Open Rheumatology, 2021, 3, 231-238.	0.9	9
35	Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy. Clinical Rheumatology, 2008, 27, 1593-1595.	1.0	8
36	The Efficacy and Safety of Muscle Relaxants in Inflammatory Arthritis: A Cochrane Systematic Review. Journal of rheumatology Supplement, The, 2012, 90, 34-39.	2.2	8

#	Article	IF	Citations
37	Early development of the Australia and New Zealand Musculoskeletal Clinical Trials Network. Internal Medicine Journal, 2020, 50, 17-23.	0.5	8
38	Disease-modifying anti-rheumatic drugs for rheumatoid arthritis: a systematic review and network meta-analysis. The Cochrane Library, 0 , , .	1.5	8
39	Problems with ethical approval and how to fix them: lessons from three trials in rheumatoid arthritis. BMJ, The, 2016, 354, i4626.	3.0	7
40	Isotretinoin-induced skeletal hyperostosis. SpringerPlus, 2014, 3, 698.	1.2	6
41	Sentiment analysis of social media posts on pharmacotherapy: A scoping review. Pharmacology Research and Perspectives, 2020, 8, e00640.	1.1	6
42	Update on the diagnosis and management of gout. Medical Journal of Australia, 2015, 203, 86-88.	0.8	4
43	Review of gout clinic in a tertiary hospital setting. Internal Medicine Journal, 2020, 50, 117-120.	0.5	4
44	Crowdsourcing trainees in a living systematic review provided valuable experiential learning opportunities: a mixed-methods study. Journal of Clinical Epidemiology, 2022, 147, 142-150.	2.4	4
45	Australian and New Zealand evidenceâ€based recommendations for pain management by pharmacotherapy in adult patients with inflammatory arthritis. International Journal of Rheumatic Diseases, 2014, 17, 738-748.	0.9	3
46	Stem cell injections for osteoarthritis of the knee. The Cochrane Library, 2019, , .	1.5	3
47	What Do the OMERACT Shoulder Core Set Candidate Instruments Measure? An Analysis Using the Refined International Classification of Functioning, Disability, and Health Linking Rules. Journal of Rheumatology, 2020, 47, 1557-1564.	1.0	3
48	Scleroderma renal crisis: observations from the South Australian Scleroderma Register. Internal Medicine Journal, 2021, 51, 235-242.	0.5	3
49	Short-term glucocorticoids for flares in people with rheumatoid arthritis receiving disease-modifying anti-rheumatic drugs (DMARDs). The Cochrane Library, 2021, 2021, .	1.5	3
50	Australian recommendations on tapering of biologic and targeted synthetic diseaseâ€modifying antiâ€rheumatic drugs in inflammatory arthritis. Internal Medicine Journal, 2022, , .	0.5	3
51	Autologous blood product injections including platelet-rich plasma for osteoarthritis of the knee. The Cochrane Library, 0, , .	1.5	2
52	Long-term glucocorticoids for rheumatoid arthritis. The Cochrane Library, 2021, 2021, .	1.5	2
53	Synovial fluid myeloid dendritic cells display important differences compared to monocyte-derived dendritic cells prepared in vitro. Clinical and Translational Immunology, 2014, 3, e23.	1.7	1
54	European consensus statements for interstitial lung disease in systemic sclerosis. Lancet Rheumatology, The, 2020, 2, e317-e318.	2.2	1

#	Article	IF	CITATIONS
55	Dose reduction and discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritis. The Cochrane Library, 2022, 2022, .	1.5	1
56	Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies. Seminars in Arthritis and Rheumatism, 2022, 55, 151988.	1.6	1
57	Marine oil supplements for rheumatoid arthritis. The Cochrane Library, 2012, , .	1.5	0
58	Authors' reply to Beales. BMJ: British Medical Journal, 2017, 356, j1196.	2.4	0
59	Marine oil supplements for rheumatoid arthritis. The Cochrane Library, 2019, , .	1.5	0
60	Response to $\hat{a} \in \mathbb{C}$ Correspondence on $\hat{a} \in \mathbb{C}$ Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis $\hat{a} \in \mathbb{C}$ by Reuter et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2020-219815.	0.5	0
61	COVID-19 vaccination for people with autoimmune inflammatory rheumatic diseases on immunomodulatory therapies. The Cochrane Library, 2021, 2021, .	1.5	0
62	Dose reduction and discontinuation of biologic and targeted syntheticÂdisease-modifying anti-rheumatic drugs (DMARDs) in people with axial spondyloarthritis and low disease activity. The Cochrane Library, 2021, 2021, .	1.5	0
63	Industry involvement in rheumatology consensus-based recommendations: a systematic review. Lancet Rheumatology, The, 2022, 4, e145-e152.	2.2	0
64	Patient Perspectives of Disease Activity, Medications and Substance Use in People with Fibromyalgia. Open Access Rheumatology: Research and Reviews, 2022, Volume 14, 87-95.	0.8	0